Streetbeat News

CVKD

Cadrenal Therapeutics, Inc. Common Stock

https://www.cadrenal.com

Industry

Biotechnology

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Open

16.00

Mkt cap

27M

Volume

50K

High

16.44

P/E Ratio

-2.42

52-wk high

32.55

Low

15.64

Div yield

N/A

52-wk low

5.40

Cadrenal Therapeutics (NASDAQ:CVKD) and Abbott (NYSE:ABT) are collaborating on a pivotal study of tecarfarin, a novel anticoagulant, for patients with recently implanted LVADs. Tecarfarin aims to prevent heart attacks, strokes, and deaths due to blood clots in these patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:27 pm

HC Wainwright & Co. has reiterated its Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 10:46 am

Cadrenal Therapeutics presented new trial data at the ISHLT Conference, highlighting the importance of anticoagulation quality in LVAD patients. The ARIES-HM3 Clinical Study, sponsored by Abbott, showed that tecarfarin, which recently received Orphan Drug Designation from the FDA, has the potential to improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 1:16 pm

The article highlights the performance of 12 health care stocks during Monday's after-market session. Larimar Therapeutics (LRMR) saw the highest gain with a 23.6% increase, while NovaBay Pharmaceuticals (NBY) experienced the largest decline, falling by 9.9%. The article also mentions earnings reports for several companies.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 8:31 pm

Cadrenal Therapeutics (NASDAQ:CVKD) reported Q1 EPS of $(0.10), missing the consensus estimate of $(0.07) by 42.86%. This represents a 79.17% improvement over the $(0.48) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 4:24 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 3:29 pm

Cadrenal Therapeutics reported that its cash used in operating activities amounted to $1.8M in Q1 2024. By the end of March 2024, the company's cash balances stood at $6.6M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 1:34 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Acrivon Therapeutics led the gainers with a 72% increase, while Vincerx Pharma saw the largest drop among the losers, declining by 74.6%. Notable mentions include Inspire Veterinary and Tilray Brands, which released their Q4 and Q3 earnings reports, respectively.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 4:31 pm

Cadrenal Therapeutics' shares surged following the FDA's Orphan Drug Designation for Tecarfarin, aimed at preventing thromboembolism and thrombosis in patients with mechanical circulatory support devices.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 1:19 pm

Cadrenal Therapeutics has been granted FDA Orphan Drug Designation for Tecarfarin, aimed at preventing thromboembolism and thrombosis in patients with various heart assist devices. This designation could lead to seven years of market exclusivity and more partnering opportunities post-approval.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.